| Fallopian Tube Carcinoma
Elahere vs Zejula
Side-by-side clinical, coverage, and cost comparison for fallopian tube carcinoma.Deep comparison between: Elahere vs Zejula with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZejula has a higher rate of injection site reactions vs Elahere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zejula but not Elahere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Elahere
Zejula
At A Glance
IV infusion
Every 3 weeks
FRalpha-directed ADC
Oral
Daily
PARP inhibitor
Indications
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Carcinoma
- Primary Peritoneal Cancer
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Carcinoma
- Primary Peritoneal Cancer
Dosing
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer 6 mg/kg adjusted ideal body weight (AIBW) as an IV infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity; premedicate with a corticosteroid, antihistamine, antipyretic, and antiemetic prior to each infusion.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line maintenance, HRD-positive) 200 mg orally once daily for patients weighing <77 kg or with platelet count <150,000/mcL; 300 mg orally once daily for patients weighing >=77 kg AND with platelet count >=150,000/mcL; start no later than 12 weeks after most recent platinum-containing regimen.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (recurrent, germline BRCA-mutated) 300 mg orally once daily; start no later than 8 weeks after most recent platinum-containing regimen.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, decreased neutrophils
Serious intestinal obstruction, abdominal pain, pleural effusion, ascites, infection, neutropenic sepsis, cardiopulmonary failure, respiratory failure, ischemic stroke, pulmonary embolus
Most common (>10%) Nausea, thrombocytopenia, anemia, fatigue, constipation, musculoskeletal pain, abdominal pain, vomiting, neutropenia, decreased appetite, leukopenia, insomnia, headache, dyspnea, rash, diarrhea, hypertension, cough, dizziness, acute kidney injury, urinary tract infection, hypomagnesemia
Serious Thrombocytopenia, anemia, MDS/AML, bone marrow suppression, hypertension, posterior reversible encephalopathy syndrome, cardiac arrest, intestinal perforation
Postmarketing Pancytopenia, hypersensitivity (including anaphylaxis), posterior reversible encephalopathy syndrome, confusional state, hallucination, cognitive impairment, non-infectious pneumonitis, photosensitivity, hypertensive crisis
Pharmacology
Mirvetuximab soravtansine-gynx is a folate receptor alpha (FRalpha)-directed antibody-drug conjugate (ADC) consisting of an anti-FRalpha chimeric IgG1 antibody linked via a cleavable sulfo-SPDB linker to DM4, a microtubule inhibitor; upon binding to FRalpha and internalization, DM4 is released intracellularly to disrupt the microtubule network, inducing cell cycle arrest and apoptotic cell death.
Niraparib is an inhibitor of PARP enzymes (PARP-1 and PARP-2) that play a role in DNA repair; inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes results in DNA damage, apoptosis, and cell death in tumor cell lines with or without BRCA1/2 deficiencies.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Elahere
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Zejula
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Elahere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zejula
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Elahere
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Zejula
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Ovarian Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Ovarian Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ElahereView full Elahere profile
ZejulaView full Zejula profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.